Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Vincent, M. D.
Butts, C.
Seymour, L.
Ding, K.
Graham, B.
Twumasi-Ankrah, P.
Gandara, D.
Schiller, J.
Green, M.
Shepherd, F.
机构：
[1] London Reg Canc Program, London, ON, Canada
[2] Cross Canc Ctr, Edmonton, AB, Canada
[3] NCIC, Clin Trials Grp, Kingston, ON, Canada
[4] UC Davis, Ctr Canc, Sacramento, CA USA
[5] Simmons Comprehens Canc Ctr, Dallas, TX USA
[6] NMCR, Atlanta, GA USA
[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7501
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
    Butts, Charles A.
    Ding, Keyue
    Seymour, Lesley
    Twumasi-Ankrah, Philip
    Graham, Barbara
    Gandara, David
    Johnson, David H.
    Kesler, Kenneth A.
    Green, Mark
    Vincent, Mark
    Cormier, Yvon
    Goss, Glenwood
    Findlay, Brian
    Johnston, Michael
    Tsao, Ming-Sound
    Shepherd, Frances A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 29 - 34
  • [2] An economic analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) JBR.10, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer (NSCLC).
    Ng, R.
    Mittmann, N.
    Florescu, M.
    Shepherd, F. A.
    Salvarrey, A.
    Seymour, L.
    Winton, T.
    Evans, B.
    Leighl, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 402S - 402S
  • [3] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
    Makoto Sonobe
    Ken-ichi Okubo
    Satoshi Teramukai
    Kazuhiro Yanagihara
    Masaaki Sato
    Toshihiko Sato
    Fengshi Chen
    Kiyoshi Sato
    Takuji Fujinaga
    Tsuyoshi Shoji
    Mitsugu Omasa
    Hiroaki Sakai
    Ryo Miyahara
    Toru Bando
    Hiroshi Date
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 1199 - 1206
  • [4] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
    Sonobe, Makoto
    Okubo, Ken-ichi
    Teramukai, Satoshi
    Yanagihara, Kazuhiro
    Sato, Masaaki
    Sato, Toshihiko
    Chen, Fengshi
    Sato, Kiyoshi
    Fujinaga, Takuji
    Shoji, Tsuyoshi
    Omasa, Mitsugu
    Sakai, Hiroaki
    Miyahara, Ryo
    Bando, Toru
    Date, Hiroshi
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1199 - 1206
  • [5] The significance of K-ras mutations in the Intergroup JBR.10 Trial on adjuvant chemotherapy in completely resected early stage non-small cell lung cancer (NSCLC) patients
    Tsao, M
    Zhu, C
    Livingston, R
    Johnson, D
    Gandara, D
    Viallet, J
    Ding, K
    Seymour, L
    Winton, T
    Shepherd, F
    [J]. LUNG CANCER, 2005, 49 : S41 - S41
  • [6] Do hemoglobin (Hb) levels influence outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non small cell lung cancer (NSCLC)? The JBR.10 trial experience
    Gauthier, I
    Ding, K
    Winton, T
    Shepherd, F
    Livingston, R
    Johnson, D
    Rigas, J
    Whitehead, M
    Graham, B
    Seymour, L
    [J]. LUNG CANCER, 2005, 49 : S280 - S280
  • [7] Update of a phase III trial of adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC)
    Jie, He
    Han, Baohui
    Liu, Yongyu
    Wu, Shi Xiu
    Kuang, Yukang
    Shen, Yi
    Chen, Chun
    Wang, Qun
    Li, Qiang
    Ma Haitao
    Xu, Shaofa
    Xu, Shidong
    Wang, Ping
    Mao, Weimin
    Pang, Zuoliang
    Hou, Shengcai
    Yang, Yue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10.
    Winton, TL
    Livingston, R
    Johnson, D
    Rigas, J
    Cormier, Y
    Butts, C
    Ding, K
    Seymour, L
    Magoski, N
    Shepherd, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 621S - 621S
  • [9] ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts)
    Rosell, R
    de Lena, M
    Carpagnano, F
    Ramlau, R
    Gonzalez-Larriba, J
    Grodzki, T
    Le Groumellec, A
    Aubert, D
    Gasmi, J
    Douillard, J
    [J]. LUNG CANCER, 2005, 49 : S3 - S4
  • [10] Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer
    Kenmotsu, Hirotsugu
    Yamamoto, Nobuyuki
    Yamanaka, Takeharu
    Yoshiya, Katsuo
    Takahashi, Toshiaki
    Ueno, Tsuyoshi
    Goto, Koichi
    Daga, Haruko
    Ikeda, Norihiko
    Sugio, Kenji
    Seto, Takashi
    Toyooka, Shinichi
    Date, Hiroshi
    Mitsudomi, Tetsuya
    Okamoto, Isamu
    Yokoi, Kohei
    Saka, Hideo
    Okamoto, Hiroaki
    Takiguchi, Yuichi
    Tsuboi, Masahiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (19) : 2187 - +
12345